Holen Sie sich die Stockscreener-App
9.44
3.51%
0.32
Handel nachbörslich:
8.97
-0.47
-4.98%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NVAX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$9.12
Offen:
$9
24-Stunden-Volumen:
3.20M
Relative Volume:
0.53
Marktkapitalisierung:
$1.51B
Einnahmen:
$793.74M
Nettoeinkommen (Verlust:
$-398.71M
KGV:
-1.3003
EPS:
-7.26
Netto-Cashflow:
$-514.43M
1W Leistung:
-6.26%
1M Leistung:
-30.64%
6M Leistung:
+91.48%
1J Leistung:
+33.71%
1-Tages-Spanne:
$8.86
$9.48
1-Wochen-Bereich:
$8.86
$10.07
52-Wochen-Spanne:
$3.5324
$23.86
Novavax Inc Stock (NVAX) Company Profile
Firmenname
Novavax Inc
Sektor
Branche
Telefon
240-268-2000
Adresse
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-09 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Bestätigt | B. Riley Securities | Buy |
| 2022-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-02 | Eingeleitet | Jefferies | Hold |
| 2022-09-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2022-02-22 | Fortgesetzt | Jefferies | Buy |
| 2022-01-21 | Eingeleitet | Cowen | Outperform |
| 2021-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Bestätigt | B. Riley FBR | Buy |
| 2020-06-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Bestätigt | B. Riley FBR | Buy |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-08-14 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-28 | Herabstufung | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-11 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-26 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Hochstufung | Seaport Global Securities | Neutral → Buy |
Alle ansehen
Novavax Inc Aktie (NVAX) Neueste Nachrichten
Novavax Settles Vaccine Supply Agreement Dispute - TipRanks
Novavax, UK terminate vaccine supply agreement - Reuters
Novavax taps AstraZeneca, Pfizer alum to lead key manufacturing site - The Business Journals
Dow Up Almost 300 Points as Voters Rush to Polls - Schaeffers Research
Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024 - The Malaysian Reserve
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Novavax appoints new General Manager for Swedish site in Uppsala - Marketscreener.com
Åsa Manelius Named Managing Director of Novavax AB Site - PR Newswire
Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Novavax's vaccine was 96 percent effective in late-stage testing, as well as 86 percent effective against the British variant of COVID-19 - Telegrafi
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - MSN
Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Is Novavax Stock A Sell After An Unexpected Side Effect Torpedoed Its Testing Plans? - Investor's Business Daily
Novavax Q3 Earnings A Week AwayTime To Accept A New Reality (NASDAQ:NVAX) - Seeking Alpha
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Noteworthy Wednesday Option Activity: NVAX, MRK, INOD - Nasdaq
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax (NVAX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
(NVAX) Trading Report - Stock Traders Daily
NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Novavax, Inc. (NVAX) And Encourages Investors to Connect - AccessWire
Novavax gets EU authorization for updated COVID-19 vaccine - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc.NVAX - PR Newswire
Novavax’s COVID-19 vaccine now available for all 194 WHO members - Maryland Daily Record
Novavax’s updated COVID-19 vaccine receives positive opinion in EU - Maryland Daily Record
Novavax: CDC approval for 2nd dose of Covid vaccine - Marketscreener.com
Novavax Inc. stock outperforms competitors despite losses on the day - MarketWatch
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note - MSN
NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Novavax, Inc. (NVAX) Stockholders to Inquire about Securities Investigation - AccessWire
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - MSN
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip? - sharewise
2024-10-21 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novavax, Inc. (NVAX) And Encourages Investors to Reach Out | NDAQ:NVAX | Press Release - Stockhouse Publishing
Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold - MSN
How Bad Is This News for Novavax? - sharewise
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novavax, Inc. (NVAX) And Encourages Stockholders to Reach Out - AccessWire
2024-10-20 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novavax, Inc. (NVAX) And Encourages Stockholders to Reach Out | NDAQ:NVAX | Press Release - Stockhouse Publishing
Novavax Plans to Cut Costs by Another $300 Million - MSN
Novavax, Inc. (NASDAQ:NVAX) Stock Position Lifted by Vontobel Holding Ltd. - MarketBeat
Novavax (NVAX) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Novavax Stock Tumbles 20% After FDA Pauses Clinical Trial On Security Concerns - Barron's
Finanzdaten der Novavax Inc-Aktie (NVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Novavax Inc-Aktie (NVAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Trizzino John | EVP, CCO and CBO |
Aug 19 '24 |
Option Exercise |
0.00 |
655 |
0 |
28,627 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Aug 16 '24 |
Option Exercise |
12.96 |
2,367 |
30,676 |
15,652 |
| YOUNG JAMES F | Director |
Jun 21 '24 |
Sale |
14.09 |
7,500 |
105,675 |
61,760 |
| YOUNG JAMES F | Director |
Jun 18 '24 |
Sale |
13.72 |
7,500 |
102,881 |
69,260 |
| Dubovsky Filip | President, R&D |
Jun 17 '24 |
Option Exercise |
6.18 |
13,904 |
85,911 |
80,517 |
| Dubovsky Filip | President, R&D |
Jun 17 '24 |
Sale |
14.47 |
13,904 |
201,164 |
66,613 |
| MCGLYNN MARGARET G | Director |
Jun 12 '24 |
Option Exercise |
0.00 |
6,670 |
0 |
10,470 |
| Alton Gregg H | Director |
Jun 12 '24 |
Option Exercise |
0.00 |
6,670 |
0 |
10,470 |
| DOUGLAS RICHARD | Director |
Jun 12 '24 |
Option Exercise |
0.00 |
6,670 |
0 |
43,920 |
| King Rachel K. | Director |
Jun 12 '24 |
Option Exercise |
0.00 |
6,670 |
0 |
18,920 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):